Innovator risks over generic warnings

Share this article:

Responding to a federal court question, the Alabama Supreme Court ruled that a man who claims he was injured by a generic version of Pfizer's Reglan can sue the innovator company for not properly warning his doctor about the drug's risks.

The court said that in the context of inadequate warnings by the brand-name manufacturer put on a prescription drug manufactured by a generic company, it is “not fundamentally unfair to hold the brand-name manufacturer liable for warnings on a product it did not produce.”

An attorney for the patient told media outlets that the “learned intermediary” doctrine applies in this case since under Alabama law companies are to inform doctors about drug risks and the presumption is that if a warning is adequate, then the doctor has warned the patient.

Pfizer told the media that the ruling applies only to Alabama and does not reflect the case's merits or the fact that four federal appeals courts have held that innovator companies aren't liable for injuries to consumers who took generic Reglan.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...